心房颤动市场 - 全球产业规模、份额、趋势、机会和预测，按治疗类型（药物治疗）、非药物治疗、最终用途、地区和竞争细分，2020 年至 2030 年

2024 年全球心房颤动市场价值为 225.4 亿美元，预计到 2030 年将达到 341.8 亿美元，预测期内复合年增长率为 7.19%。心房颤动是一种常见的心律不整，其特征是心律不整且心跳过快，会显着增加中风、心臟衰竭和其他心血管併发症的风险。全球其发病率的不断上升可归因于人口老化、肥胖率上升以及生活方式引起的健康问题等因素。这种情况给医疗保健系统带来了相当大的临床和经济负担。新冠疫情虽然减少了心臟手术，但也凸显了远距医疗和远端监控等数位医疗方法的重要性，预计这些趋势将持续下去并支持市场成长。因此，对有效心房颤动管理的需求持续上升，推动了治疗和诊断的进步。

关键市场驱动因素

人口老化加剧推动全球心房颤动市场

主要市场挑战

缺乏意识

主要市场趋势

技术进步

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球心房颤动市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依治疗类型（药物治疗（抗心律不整药物）、非药物治疗（导管消融、迷宫手术、电復律）
  • 依最终用途（医院、专科诊所、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美心房颤动市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲心房颤动市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太心房颤动市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美心房颤动市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲心房颤动市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购
• 产品开发
• 最新动态

第 13 章：全球心房颤动市场：SWOT 分析

第 14 章：竞争格局

• Parexel International Corporation
• AtriCure Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Bristol- Myers Squibb Corporation
• Cardio Focus Inc.
• Sanofi Aventis
• Biosense Webster Inc.
• Endoscopic Technologies Inc.
• Abbott Laboratories
• Johnsons & Johnson Services, Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Atrial Fibrillation Market was valued at USD 22.54 Billion in 2024 and is projected to reach USD 34.18 Billion by 2030, growing at a CAGR of 7.19% during the forecast period. Atrial fibrillation, a prevalent cardiac arrhythmia marked by irregular and often rapid heartbeats, significantly increases the risk of stroke, heart failure, and other cardiovascular complications. Its growing incidence globally is attributed to factors such as the aging population, increasing obesity rates, and lifestyle-induced health issues. This condition poses a considerable clinical and financial burden on healthcare systems. The COVID-19 pandemic, while reducing cardiac surgeries, emphasized the importance of digital healthcare approaches like telemedicine and remote monitoring-trends that are expected to persist and support market growth. As a result, the demand for effective atrial fibrillation management continues to rise, driving advancements in treatment and diagnosis.

Key Market Drivers

Increasing Aging Population is Driving the Global Atrial Fibrillation Market

The growing global aging population is a major factor fueling the expansion of the atrial fibrillation market. Older individuals are more susceptible to this condition due to age-related health risks such as hypertension, obesity, and diabetes. As the proportion of elderly people rises, so does the prevalence of atrial fibrillation. According to the American Heart Association, the likelihood of developing atrial fibrillation doubles with every decade after age 50. Additionally, the World Health Organization reports that by 2030, one in six people globally will be over 60, with the number expected to reach 2.1 billion by 2050. This demographic trend is significantly influencing the demand for atrial fibrillation therapies and solutions.

Key Market Challenges

Lack of awareness

A major hurdle in combating atrial fibrillation globally is the widespread lack of awareness. Despite being common, the condition often goes undiagnosed or is insufficiently treated. This is largely due to limited public understanding of its symptoms and potential severity, resulting in delayed diagnoses and inadequate interventions. The insufficient awareness among both patients and healthcare providers continues to impede efforts to effectively manage and reduce the burden of atrial fibrillation worldwide.

Key Market Trends

Technological Advancements

Technological innovations are transforming the diagnosis and management of atrial fibrillation, leading to improved patient outcomes and more efficient healthcare delivery. As the most common form of cardiac arrhythmia, atrial fibrillation can result in serious complications, making early and accurate detection critical. Advanced tools and procedures, including minimally invasive surgical techniques and remote monitoring solutions, are gaining prominence. These developments cater to growing demand for safer, more precise treatment methods and are playing a pivotal role in expanding the global atrial fibrillation market.

Key Market Players

• Parexel International Corporation
• AtriCure Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Bristol- Myers Squibb Corporation
• Cardio Focus Inc.
• Sanofi Aventis
• Biosense Webster Inc.
• Endoscopic Technologies Inc.
• Abbott Laboratories
• Johnsons & Johnson Services, Inc.

Report Scope:

In this report, the Global Atrial Fibrillation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atrial Fibrillation Market, By Treatment Type:

• Pharmacological Treatment
• Non-Pharmacological Treatment

Atrial Fibrillation Market, By End Use:

• Hospital
• Specialty Clinics
• Others

Atrial Fibrillation Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Atrial Fibrillation Market.

Available Customizations:

Global Atrial Fibrillation market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Atrial Fibrillation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Pharmacological Treatment (Anti-arrhythmic Drugs), Non-Pharmacological Treatment(Catheter Ablation, Maze Surgery, Electric Cardioversion)
  • 5.2.2. By End-use (Hospital, Specialty Clinics, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Atrial Fibrillation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By End-Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Atrial Fibrillation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By End-Use
  • 6.3.2. Canada Atrial Fibrillation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By End-Use
  • 6.3.3. Mexico Atrial Fibrillation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By End-Use

7. Europe Atrial Fibrillation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By End-Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Atrial Fibrillation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By End-Use
  • 7.3.2. United Kingdom Atrial Fibrillation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By End-Use
  • 7.3.3. Italy Atrial Fibrillation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By End-Use
  • 7.3.4. France Atrial Fibrillation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By End-Use
  • 7.3.5. Spain Atrial Fibrillation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By End-Use

8. Asia-Pacific Atrial Fibrillation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By End-Use
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Atrial Fibrillation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By End-Use
  • 8.3.2. India Atrial Fibrillation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By End-Use
  • 8.3.3. Japan Atrial Fibrillation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By End-Use
  • 8.3.4. South Korea Atrial Fibrillation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By End-Use
  • 8.3.5. Australia Atrial Fibrillation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By End-Use

9. South America Atrial Fibrillation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By End-Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Atrial Fibrillation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By End-Use
  • 9.3.2. Argentina Atrial Fibrillation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By End-Use
  • 9.3.3. Colombia Atrial Fibrillation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By End-Use

10. Middle East and Africa Atrial Fibrillation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By End-Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Atrial Fibrillation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By End-Use
  • 10.3.2. Saudi Arabia Atrial Fibrillation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By End-Use
  • 10.3.3. UAE Atrial Fibrillation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Product Development
• 12.3. Recent Developments

13. Global Atrial Fibrillation Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Parexel International Corporation
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. AtriCure Inc.
• 14.3. Boehringer Ingelheim GmbH
• 14.4. Boston Scientific Corporation
• 14.5. Bristol- Myers Squibb Corporation
• 14.6. Cardio Focus Inc.
• 14.7. Sanofi Aventis
• 14.8. Biosense Webster Inc.
• 14.9. Endoscopic Technologies Inc.
• 14.10. Abbott Laboratories
• 14.11. Johnsons & Johnson Services, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer